Replimune RP2-202 (Uveal Melanoma) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if an experimental drug called RP2 (the study drug) is a safe and effective option for people who have uveal melanoma (melanoma in the eye). We want to know how well the study drug works when it is combined with a drug called nivolumab, and we will compare its outcomes to treatment with the drug combination of nivolumab + ipilimumab.
Metastatic Uveal Melanoma
¿Quién puede participar en el Estudio?
Adults ages 18+ who:
- Are diagnosed with uveal melanoma
- Have disease that has spread to other parts of the body
- Have not been treated with immune checkpoint inhibitor therapy since their diagnosis
- Have at least 1 tumor that is large enough to take an injection
- Have never been treated with an oncolytic virus (a virus that has been changed to target cancer cells)
For more information, contact the study team at emily.bolch@duke.edu.
¿Qué Implica?
If you choose to join this study and are found to be eligible, you will get a random assignment (fair, equal chance) to 1 of 2 groups. You have a 50% chance of being assigned to either group. You will either:
- Get the study drug (an injection into the tumor) and nivolumab (an IV through a vein in your arm) every 3 weeks; OR
- Get ipilimumab and nivolumab (both are IVs through a vein in your arm) every 3 weeks
You will have tumor measurements every 12 weeks. You will receive treatment for up to 24 months, unless you have unwanted side effects or the study doctor finds that you are not getting better.
Detalles del Estudio
